NasdaqGS:BBIOBiotechs
Will New ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Rare Disease Narrative?
BridgeBio Pharma recently presented clinical trial updates for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) at the European Society of Cardiology Congress 2025, including new data on reduced cardiovascular mortality and sustained clinical benefits from its open-label extension study.
These disclosures are significant because they showcase pivotal results for the company’s lead drug candidate, which could influence broad perceptions among healthcare professionals and investors...